SURGE Therapeutics

Private

Cambridge, MassachusettsHealthcare & Life Scienceshttps://surgetx.com/

Last Round

Series B

Jul 19, 2023

Total Funding Raised

$58M

Company Overview

SURGE Therapeutics is a biotechnology company that specializes in a proprietary technology-based platform for delivering localized immunotherapy through an injectable biodegradable hydrogel designed to enhance cancer treatment during surgical tumor resection.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

intraoperative immunotherapyhydrogel drug deliverysolid tumor treatmentcancer recurrence preventionsurgical oncologylocal immunotherapydrug delivery platformclinical-stage biotechlocal drug deliverysurgical site therapyimmuno-oncologybiotech startupdrug-device combination

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SURGE Therapeutics Comparables

Compare SURGE Therapeutics with similar companies based on industry and business-model similarity.

SURGE Therapeutics comparables — related companies by embedding similarity
Company	Similarity	Market Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

SURGE Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series B	Jul 19, 2023
Series A	Oct 17, 2022

View all Funding Rounds

Key People

Founding team and executive leadership

Michael Goldberg

Chief Executive Officer

Executive Team

SURGE Therapeutics Investors

Notable investors and investment history

SURGE Therapeutics investors
Investor	Rounds
Camford Capital	Series B, Series A
Bioluminescence Ventures	Series B
Khosla Ventures	Series A, Series B
Intuitive Ventures	Series B, Series A
Cancer Research Institute	Series A, Series B
8VC	Series A, Series B
Camford Capital	Series B, Series A

View all Investors

SURGE Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

SURGE Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SURGE Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts

Employee Range9

Year Founded2018

Last FundingJul 19, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.